Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Idarubicin
Other: Laboratory Biomarker Analysis
Drug: Vorinostat

Registration Number: NCT01802333

Lead Sponsor: National Cancer Institute (NCI)

Brief Summary: This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, daunorubicin hydrochloride, idarubicin, and vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells. It is not yet known which combination chemotherapy is more effective in treating acute myeloid leukemia.

Detailed Description: PRIMARY OBJECTIVES:

I. To compare event-free survival (EFS) between patients with acute myeloid leukemia (AML) who receive standard 7+3 (cytarabine and daunorubicin hydrochloride) or idarubicin and high-dose cytarabine (IA) to patients who receive IA + vorinostat. (Chemotherapy) II. To determine whether it is possible to get 60% or more of adults with high-risk AML (by cytogenetics) in first complete remission (CR1) to allogeneic hematopoietic cell transplantation (HCT). (Transplant)

SECONDARY OBJECTIVES:

I. To estimate the frequency and severity of toxicities of the three regimens in this patient population. (Chemotherapy) II. To estimate disease-free survival (DFS) among patients who receive transplant. (Transplant) III. To compare event-free survival (EFS) between patients who receive standard 7 + 3 to patients who receive IA. (Chemotherapy) IV. To estimate the prevalence of the mutations nucleophosmin (nucleolar phosphoprotein B23, numatrin) (NPM1), isocitrate dehydrogenase 1 (NADP+), soluble (IDH1), isocitrate dehydrogenase 2 (NADP+), mitochondrial (IDH2), tet methylcytosine dioxygenase 2 (TET2) and deoxyribonucleic acid (DNA) (cytosine-5-)-methyltransferase 3 alpha (DNMT3A) and the cytogenetic risk distribution of patients on this study and to evaluate the association between these and overall survival (OS), event-free survival (EFS), disease-free survival (DFS), and complete remission rate. (Chemotherapy/Translational Medicine) V. To compare the complete response rate, disease-free survival (DFS), and overall survival (OS) between patients who receive standard 7+3 therapy or IA to patients who receive IA + vorinostat. (Chemotherapy)

TERTIARY OBJECTIVES:

I. Future planned studies will include testing of histone H3 acetylation, induction of gamma H2A histone family, member X (H2AX), analysis of reactive oxygen species (ROS) resistance and DNA methylation profiles. (Chemotherapy/Translational Medicine)

OUTLINE: Patients are randomized to 1 of 3 treatment arms.

INDUCTION/RE-INDUCTION:

ARM I: Patients receive standard dose cytarabine intravenously (IV) continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 15. Patients achieving complete remission (CR) or complete remission with incomplete platelet recover (CRi) may proceed to allogeneic hematopoietic stem cell transplant (HSCT) or to consolidation therapy.

ARM II: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.

ARM III: Patients receive vorinostat orally (PO) thrice daily (TID) on days 1-3, high-dose cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. (Permanently closed to accrual, effective 6/2/2015) Patient previously randomized to Arm III may continue treatment without vorinostat.

CONSOLIDATION:

ARM I: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5.

ARM II: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15 minutes on days 1-2.

ARM III: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days 4-6, and idarubicin IV over 15 minutes on days 4-5. (Permanently closed to accrual, effective 6/2/2015) Patient previously randomized to Arm III may continue treatment with or without vorinostat.

In all arms, treatment repeats every 28 days for 4 courses or until transplant in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy.

After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 2 years, and then annually for 2 years.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 754

Inclusion Criteria

STEP 1 - INDUCTION/RE-INDUCTION
Patients must have morphologically confirmed newly diagnosed acute myelogenous leukemia (AML) with blood or bone marrow disease; patients with only extramedullary disease in the absence of bone marrow or blood involvement are not eligible; note: this protocol uses World Health Organization (WHO) diagnostic criteria for AML; patients with acute promyelocytic leukemia (APL, French-American-British [FAB], M3) or blastic transformation of chronic myelogenous leukemia (CML) are not eligible; patients with known core binding factor (CBF) or fms-like tyrosine kinase 3 (FLT3) related leukemias are eligible for this study, but should preferentially be placed on National Cancer Institute (NCI)-sponsored protocols specific for these subtypes, if available
Patients must have diagnostic/pre-treatment specimens obtained within 28 days prior to registration submitted for cytogenetic (and fluorescent in situ hybridization [FISH] if possible) analysis to determine risk status; high risk classification will be defined as del(5q)/-5, del(7q)/-7, abn3q26 [inv(3)/t(3;3)], 11q23 rearrangement [except t(9;11)], 17p-, t(6;9), t(9;22), complex (at least 3 unrelated abnormalities [abn]), and monosomal karyotype (either loss of two different chromosomes or loss of one chromosome along with a structural chromosome abnormality other than add, ring and mar); karyograms and cytogenetics/FISH analysis reports must be submitted for discipline review
Patients must be chemo-naïve, i.e., not have received any prior induction chemotherapy for AML or myelodysplastic syndrome (MDS); temporary prior measures such as apheresis or hydroxyurea are allowed; prior anthracycline therapy is allowed, but must not exceed a dose of 200 mg/m^2 daunorubicin or equivalent; prior all-trans retinoic acid (ATRA) for suspected APL is allowed; prior methotrexate for central nervous system (CNS) involvement is allowed; patients with prior history of MDS must not have received azacitidine, decitabine, lenalidomide or vorinostat
Patients must have peripheral blood and bone marrow aspirate specimens obtained within 28 days prior to registration submitted for translational medicine; with patient consent, residuals will be banked for future research
Patients must have Zubrod performance status =< 3
Patients must have either echocardiogram (ECHO) or multi gated acquisition scan (MUGA) with ejection fraction >= 45% within 28 days prior to registration
Patients must not have prolonged corrected QT (QTc) interval (> 500 msec) determined by electrocardiogram (EKG) within 28 days prior to registration
Patients must not have cardiac disease defined as: New York Heart Association (NYHA) > class II; patients must not have unstable angina (angina symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months
Patients must not have any coexisting medical condition that is likely to interfere with study procedures or results, and must be reasonable candidates for intensive chemotherapy, in the opinion of their treating physicians
Patients who are known to be human immunodeficiency virus (HIV) positive (+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:
- Cluster of differentiation (CD) 4 cells >= 500/mm^3
- Viral load < 50 copies of HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies of HIV mRNA if not on cART
- No zidovudine or stavudine as part of cART; patients who are HIV+ and do not meet all of these criteria are not eligible for this study
Patients with known hepatitis B or hepatitis C infection may be eligible providing they have viral load < 800,000 IU/mL within 28 days prior to registration
Patients must be able to take oral medications
Patients must have a history and physical examination obtained within 28 days prior to registration
Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
Prior malignancy is allowed providing it does not require concurrent therapy; exception: active hormonal therapy is allowed
Patients must not be receiving valproic acid
All patients must be informed of the investigational nature of this study; patients or a legally authorized representative must sign and give written informed consent in accordance with institutional and federal guidelines
As part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
STEP 2 - CONSOLIDATION
Patients may be registered for consolidation provided that they were eligible for the initial induction/re-induction registration and satisfy the following additional criteria:
- Patients must have achieved morphologic remission (complete remission [CR] or complete remission with incomplete blood count recover [CRi]) after completion of induction or re-induction therapy; patient must remain in remission until beginning consolidation and this must be documented by bone marrow and peripheral blood examination within 28 days prior to registration to Step 2
- All non-hematologic treatment related toxicities that are deemed clinically significant by the treating physician must have resolved to =< grade 2
- Patients must not have received allogeneic stem cell transplant

Exclusion Criteria

Not provided

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm I (standard dose cytarabine, daunorubicin hydrochloride)	Daunorubicin Hydrochloride	INDUCTION/RE-INDUCTION: Patients receive standard dose cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 15. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy.
Arm I (standard dose cytarabine, daunorubicin hydrochloride)	Allogeneic Hematopoietic Stem Cell Transplantation	INDUCTION/RE-INDUCTION: Patients receive standard dose cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 15. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy.
Arm I (standard dose cytarabine, daunorubicin hydrochloride)	Laboratory Biomarker Analysis	INDUCTION/RE-INDUCTION: Patients receive standard dose cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 15. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy.
Arm II (high-dose cytarabine, idarubicin)	Allogeneic Hematopoietic Stem Cell Transplantation	INDUCTION/RE-INDUCTION: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15 minutes on days 1-2. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy.
Arm II (high-dose cytarabine, idarubicin)	Laboratory Biomarker Analysis	INDUCTION/RE-INDUCTION: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15 minutes on days 1-2. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy.
Arm III (vorinostat, high-dose cytarabine, idarubicin)	Allogeneic Hematopoietic Stem Cell Transplantation	INDUCTION/RE-INDUCTIONI: Patients receive vorinostat PO TID on days 1-3, high-dose cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days 4-6, and idarubicin IV over 15 minutes on days 4-5. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy. (Permanently closed to accrual, effective 6/2/2015) Patients previously randomized to Arm III may continue treatment with or without vorinostat.
Arm III (vorinostat, high-dose cytarabine, idarubicin)	Laboratory Biomarker Analysis	INDUCTION/RE-INDUCTIONI: Patients receive vorinostat PO TID on days 1-3, high-dose cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days 4-6, and idarubicin IV over 15 minutes on days 4-5. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy. (Permanently closed to accrual, effective 6/2/2015) Patients previously randomized to Arm III may continue treatment with or without vorinostat.
Arm I (standard dose cytarabine, daunorubicin hydrochloride)	Cytarabine	INDUCTION/RE-INDUCTION: Patients receive standard dose cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 15. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy.
Arm II (high-dose cytarabine, idarubicin)	Cytarabine	INDUCTION/RE-INDUCTION: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15 minutes on days 1-2. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy.
Arm II (high-dose cytarabine, idarubicin)	Idarubicin	INDUCTION/RE-INDUCTION: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15 minutes on days 1-2. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy.
Arm III (vorinostat, high-dose cytarabine, idarubicin)	Cytarabine	INDUCTION/RE-INDUCTIONI: Patients receive vorinostat PO TID on days 1-3, high-dose cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days 4-6, and idarubicin IV over 15 minutes on days 4-5. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy. (Permanently closed to accrual, effective 6/2/2015) Patients previously randomized to Arm III may continue treatment with or without vorinostat.
Arm III (vorinostat, high-dose cytarabine, idarubicin)	Idarubicin	INDUCTION/RE-INDUCTIONI: Patients receive vorinostat PO TID on days 1-3, high-dose cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days 4-6, and idarubicin IV over 15 minutes on days 4-5. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy. (Permanently closed to accrual, effective 6/2/2015) Patients previously randomized to Arm III may continue treatment with or without vorinostat.
Arm III (vorinostat, high-dose cytarabine, idarubicin)	Vorinostat	INDUCTION/RE-INDUCTIONI: Patients receive vorinostat PO TID on days 1-3, high-dose cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy. CONSOLIDATION: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days 4-6, and idarubicin IV over 15 minutes on days 4-5. TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy. (Permanently closed to accrual, effective 6/2/2015) Patients previously randomized to Arm III may continue treatment with or without vorinostat.

Primary Outcome Measures

Name	Time	Method
Event-free Survival (EFS)	EFS assessed for up to 5 years, 2 year EFS reported	EFS is calculated for all patients from the date of initial registration on study until the first of the following: death from any cause, relapse from remission (CR or CRi) or completion of protocol Induction/Re-Induction therapy without documentation of CR or CRi. 2-year EFS by arm will be estimated using the Kaplan-Meier method. EFS will be compared between Arm I and Arm III and between Arm II and Arm III using Cox proportional hazards regression.
Rate of Allogeneic HCT	Up to 5 years	The goal of the transplant objective is to determine whether it is possible to conduct allogeneic HCT on 60% or more of adults with high-risk AML in first complete remission (alternative). If 40% or fewer of high-risk patients in CR can be transplanted, the proposed transplant support system will not be considered feasible. A one-sided binomial test compared to the null transplant rate will be conducted.

Secondary Outcome Measures

Name	Time	Method
Disease-free Survival (DFS) Among High Risk Patients	DFS assessed for up to 5 years, 2 year DFS reported	DFS is calculated for patients who have achieved a CR or CRi (complete response with incomplete blood count recovery). DFS will be measured from the date of CR or CRi until relapse from CR or CRi for death from any cause. Observation is censored at the date of last follow-up for patients last known to be alive without report of relapse. 2-year DFS for high risk patients will be estimated using the Kaplan-Meier method.
EFS of Arm I Compared to Arm II	EFS assessed for up to 5 years, 2 year EFS reported	EFS is calculated for all patients from the date of initial registration on study until the first of the following: death from any cause, relapse from remission (CR or CRi) or completion of protocol Induction/Re-Induction therapy without documentation of CR or CRi. A two-sided test of the hazard ratio (HR) of 7:3: IA (versus the null hypothesis of HR =1) will be done using a proportional hazards regression model with the stratification factors included as covariates. 2-year EFS by arm will be estimated using the Kaplan-Meier method.
Frequency and Severity of Toxicities	Up to 5 years	Number of patients with Grade 3-5 adverse events that were possibly, probably or definitely related to study drug are reported by given type of adverse event.

Trial Locations

Locations (446): Flaget Memorial Hospital
🇺🇸
Bardstown, Kentucky, United States
Massachusetts General Hospital Cancer Center
🇺🇸
Boston, Massachusetts, United States
Brigham and Women's Hospital
🇺🇸
Boston, Massachusetts, United States
M D Anderson Cancer Center
🇺🇸
Houston, Texas, United States
Harborview Medical Center
🇺🇸
Seattle, Washington, United States
Pacific Gynecology Specialists
🇺🇸
Seattle, Washington, United States
Alaska Oncology and Hematology LLC
🇺🇸
Anchorage, Alaska, United States
Alaska Women's Cancer Care
🇺🇸
Anchorage, Alaska, United States
The University of Arizona Medical Center-University Campus
🇺🇸
Tucson, Arizona, United States
Yuma Cancer Center
🇺🇸
Yuma, Arizona, United States
Stanford Cancer Institute Palo Alto
🇺🇸
Palo Alto, California, United States
Alaska Regional Hospital
🇺🇸
Anchorage, Alaska, United States
Smilow Cancer Hospital Care Center at Saint Francis
🇺🇸
Hartford, Connecticut, United States
Hartford Hospital
🇺🇸
Hartford, Connecticut, United States
University of Arizona Cancer Center-Orange Grove Campus
🇺🇸
Tucson, Arizona, United States
Fremont - Rideout Cancer Center
🇺🇸
Marysville, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
🇺🇸
Orange, California, United States
Northside Hospital
🇺🇸
Atlanta, Georgia, United States
Saint Alphonsus Cancer Care Center-Boise
🇺🇸
Boise, Idaho, United States
Illinois CancerCare-Canton
🇺🇸
Canton, Illinois, United States
Memorial Hospital of Carbondale
🇺🇸
Carbondale, Illinois, United States
Illinois CancerCare-Bloomington
🇺🇸
Bloomington, Illinois, United States
Saint Luke's Mountain States Tumor Institute-Twin Falls
🇺🇸
Twin Falls, Idaho, United States
NorthShore University HealthSystem-Evanston Hospital
🇺🇸
Evanston, Illinois, United States
University of Chicago Comprehensive Cancer Center
🇺🇸
Chicago, Illinois, United States
Saint Joseph Medical Center
🇺🇸
Bloomington, Illinois, United States
Decatur Memorial Hospital
🇺🇸
Decatur, Illinois, United States
NorthShore University HealthSystem-Glenbrook Hospital
🇺🇸
Glenview, Illinois, United States
Centralia Oncology Clinic
🇺🇸
Centralia, Illinois, United States
Northwestern University
🇺🇸
Chicago, Illinois, United States
Illinois CancerCare-Peoria
🇺🇸
Peoria, Illinois, United States
Wichita NCI Community Oncology Research Program
🇺🇸
Wichita, Kansas, United States
Cancer Center of Kansas - Pratt
🇺🇸
Pratt, Kansas, United States
Menorah Medical Center
🇺🇸
Overland Park, Kansas, United States
Cancer Care Center of Decatur
🇺🇸
Decatur, Illinois, United States
Tufts Medical Center
🇺🇸
Boston, Massachusetts, United States
Cancer Center of Kansas-Kingman
🇺🇸
Kingman, Kansas, United States
Cancer Center of Kansas-Liberal
🇺🇸
Liberal, Kansas, United States
Cancer Center of Kansas - Wichita
🇺🇸
Wichita, Kansas, United States
University of Kansas Cancer Center
🇺🇸
Kansas City, Kansas, United States
Cancer Center of Kansas - El Dorado
🇺🇸
El Dorado, Kansas, United States
Saint Luke's South Hospital
🇺🇸
Overland Park, Kansas, United States
Associates In Womens Health
🇺🇸
Wichita, Kansas, United States
Via Christi Regional Medical Center
🇺🇸
Wichita, Kansas, United States
Minnesota Oncology Hematology PA-Maplewood
🇺🇸
Maplewood, Minnesota, United States
Fairview Ridges Hospital
🇺🇸
Burnsville, Minnesota, United States
Cancer Center of Kansas - Salina
🇺🇸
Salina, Kansas, United States
Cancer Center of Kansas - Newton
🇺🇸
Newton, Kansas, United States
Genesys Hurley Cancer Institute
🇺🇸
Flint, Michigan, United States
Southeast Cancer Center
🇺🇸
Cape Girardeau, Missouri, United States
Unity Hospital
🇺🇸
Fridley, Minnesota, United States
Lakeview Hospital
🇺🇸
Stillwater, Minnesota, United States
Mercy Hospital-Joplin
🇺🇸
Joplin, Missouri, United States
Hematology/Oncology Clinic LLP
🇺🇸
Baton Rouge, Louisiana, United States
Minnesota Oncology Hematology PA-Woodbury
🇺🇸
Woodbury, Minnesota, United States
Capital Region Medical Center-Goldschmidt Cancer Center
🇺🇸
Jefferson City, Missouri, United States
Saint Louis Cancer and Breast Institute-South City
🇺🇸
Saint Louis, Missouri, United States
Dana-Farber Cancer Institute
🇺🇸
Boston, Massachusetts, United States
Central Care Cancer Center-Carrie J Babb Cancer Center
🇺🇸
Bolivar, Missouri, United States
Freeman Health System
🇺🇸
Joplin, Missouri, United States
Siteman Cancer Center at West County Hospital
🇺🇸
Creve Coeur, Missouri, United States
McDowell Hospital
🇺🇸
Marion, North Carolina, United States
Saint Vincent Frontier Cancer Center
🇺🇸
Billings, Montana, United States
CHI Health Good Samaritan
🇺🇸
Kearney, Nebraska, United States
University of Missouri - Ellis Fischel
🇺🇸
Columbia, Missouri, United States
Saint Francis Medical Center
🇺🇸
Cape Girardeau, Missouri, United States
Saint Luke's East - Lee's Summit
🇺🇸
Lee's Summit, Missouri, United States
Bozeman Deaconess Hospital
🇺🇸
Bozeman, Montana, United States
Park Ridge Hospital Breast Health Center
🇺🇸
Hendersonville, North Carolina, United States
Midlands Community Hospital
🇺🇸
Papillion, Nebraska, United States
Transylvania Regional Hospital
🇺🇸
Brevard, North Carolina, United States
Providence Newberg Medical Center
🇺🇸
Newberg, Oregon, United States
Dayton NCI Community Oncology Research Program
🇺🇸
Dayton, Ohio, United States
Blanchard Valley Hospital
🇺🇸
Findlay, Ohio, United States
Ephrata Community Hospital
🇺🇸
Ephrata, Pennsylvania, United States
Saint Francis Hospital
🇺🇸
Federal Way, Washington, United States
Grandview Hospital
🇺🇸
Dayton, Ohio, United States
Oncology Hematology Care Inc-Healthplex
🇺🇸
Fairfield, Ohio, United States
Cherry Tree Cancer Center
🇺🇸
Hanover, Pennsylvania, United States
Penn State Milton S Hershey Medical Center
🇺🇸
Hershey, Pennsylvania, United States
MetroHealth Medical Center
🇺🇸
Cleveland, Ohio, United States
Good Samaritan Hospital - Dayton
🇺🇸
Dayton, Ohio, United States
Atrium Medical Center-Middletown Regional Hospital
🇺🇸
Franklin, Ohio, United States
Bay Area Hospital
🇺🇸
Coos Bay, Oregon, United States
Adams Cancer Center
🇺🇸
Gettysburg, Pennsylvania, United States
Wayne Hospital
🇺🇸
Greenville, Ohio, United States
Natalie Warren Bryant Cancer Center at Saint Francis
🇺🇸
Tulsa, Oklahoma, United States
Geisinger Medical Center
🇺🇸
Danville, Pennsylvania, United States
Cleveland Clinic Foundation
🇺🇸
Cleveland, Ohio, United States
Lewistown Hospital
🇺🇸
Lewistown, Pennsylvania, United States
Drexel University School of Medicine
🇺🇸
Philadelphia, Pennsylvania, United States
Ephrata Cancer Center
🇺🇸
Ephrata, Pennsylvania, United States
WellSpan Health-York Cancer Center
🇺🇸
York, Pennsylvania, United States
Fred Hutchinson Cancer Research Center
🇺🇸
Seattle, Washington, United States
McKay-Dee Hospital Center
🇺🇸
Ogden, Utah, United States
Harrison HealthPartners Hematology and Oncology-Bremerton
🇺🇸
Bremerton, Washington, United States
Providence Regional Cancer System-Centralia
🇺🇸
Centralia, Washington, United States
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
🇺🇸
Houston, Texas, United States
Swedish Cancer Institute-Issaquah
🇺🇸
Issaquah, Washington, United States
Seattle Cancer Care Alliance at EvergreenHealth
🇺🇸
Kirkland, Washington, United States
Swedish Medical Center-Edmonds
🇺🇸
Edmonds, Washington, United States
American Fork Hospital / Huntsman Intermountain Cancer Center
🇺🇸
American Fork, Utah, United States
Swedish Cancer Institute-Eastside Oncology Hematology
🇺🇸
Bellevue, Washington, United States
Providence Regional Cancer System-Aberdeen
🇺🇸
Aberdeen, Washington, United States
Kadlec Clinic Hematology and Oncology
🇺🇸
Kennewick, Washington, United States
Skagit Valley Hospital
🇺🇸
Mount Vernon, Washington, United States
Harrison HealthPartners Hematology and Oncology-Poulsbo
🇺🇸
Poulsbo, Washington, United States
Franciscan Research Center-Northwest Medical Plaza
🇺🇸
Tacoma, Washington, United States
Northwest Medical Specialties PLLC
🇺🇸
Tacoma, Washington, United States
Indiana University/Melvin and Bren Simon Cancer Center
🇺🇸
Indianapolis, Indiana, United States
Franciscan Health Indianapolis
🇺🇸
Indianapolis, Indiana, United States
Good Samaritan Hospital - Cincinnati
🇺🇸
Cincinnati, Ohio, United States
Oncology Hematology Care Inc-Kenwood
🇺🇸
Cincinnati, Ohio, United States
Oncology Hematology Care Inc - Anderson
🇺🇸
Cincinnati, Ohio, United States
The Jewish Hospital
🇺🇸
Cincinnati, Ohio, United States
Bethesda North Hospital
🇺🇸
Cincinnati, Ohio, United States
Oncology Hematology Care Inc-Blue Ash
🇺🇸
Cincinnati, Ohio, United States
TriHealth Cancer Institute-Anderson
🇺🇸
Cincinnati, Ohio, United States
Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
Vanderbilt Breast Center at One Hundred Oaks
🇺🇸
Nashville, Tennessee, United States
Utah Cancer Specialists-Salt Lake City
🇺🇸
Salt Lake City, Utah, United States
Allan Blair Cancer Centre
🇨🇦
Regina, Saskatchewan, Canada
Cancer Center of Kansas-Independence
🇺🇸
Independence, Kansas, United States
Mercy Hospital
🇺🇸
Coon Rapids, Minnesota, United States
Fairview-Southdale Hospital
🇺🇸
Edina, Minnesota, United States
Cancer Center of Kansas - Chanute
🇺🇸
Chanute, Kansas, United States
Cancer Center of Kansas - Wellington
🇺🇸
Wellington, Kansas, United States
Abbott-Northwestern Hospital
🇺🇸
Minneapolis, Minnesota, United States
Poudre Valley Hospital
🇺🇸
Fort Collins, Colorado, United States
Lawrence Memorial Hospital
🇺🇸
Lawrence, Kansas, United States
Cancer Center of Kansas - Parsons
🇺🇸
Parsons, Kansas, United States
Rice Memorial Hospital
🇺🇸
Willmar, Minnesota, United States
Cancer Center of Kansas - Dodge City
🇺🇸
Dodge City, Kansas, United States
New Ulm Medical Center
🇺🇸
New Ulm, Minnesota, United States
Hennepin County Medical Center
🇺🇸
Minneapolis, Minnesota, United States
Welch Cancer Center
🇺🇸
Sheridan, Wyoming, United States
Billings Clinic-Cody
🇺🇸
Cody, Wyoming, United States
Health Partners Inc
🇺🇸
Minneapolis, Minnesota, United States
Regions Hospital
🇺🇸
Saint Paul, Minnesota, United States
Wayne State University/Karmanos Cancer Institute
🇺🇸
Detroit, Michigan, United States
University of Oklahoma Health Sciences Center
🇺🇸
Oklahoma City, Oklahoma, United States
Oregon Health and Science University
🇺🇸
Portland, Oregon, United States
Mercy Medical Center - Des Moines
🇺🇸
Des Moines, Iowa, United States
Liberty Radiation Oncology Center
🇺🇸
Liberty, Missouri, United States
Saint Joseph Hospital East
🇺🇸
Lexington, Kentucky, United States
Saint James Community Hospital and Cancer Treatment Center
🇺🇸
Butte, Montana, United States
Anchorage Radiation Therapy Center
🇺🇸
Anchorage, Alaska, United States
University of Alabama at Birmingham Cancer Center
🇺🇸
Birmingham, Alabama, United States
Alaska Breast Care and Surgery LLC
🇺🇸
Anchorage, Alaska, United States
Illinois CancerCare-Carthage
🇺🇸
Carthage, Illinois, United States
Crossroads Cancer Center
🇺🇸
Effingham, Illinois, United States
Western Illinois Cancer Treatment Center
🇺🇸
Galesburg, Illinois, United States
Hematology Oncology Associates of Illinois-Highland Park
🇺🇸
Highland Park, Illinois, United States
NorthShore University HealthSystem-Highland Park Hospital
🇺🇸
Highland Park, Illinois, United States
Illinois CancerCare-Kewanee Clinic
🇺🇸
Kewanee, Illinois, United States
NorthShore Hematology Oncology-Libertyville
🇺🇸
Libertyville, Illinois, United States
Illinois CancerCare-Macomb
🇺🇸
Macomb, Illinois, United States
Loyola University Medical Center
🇺🇸
Maywood, Illinois, United States
Good Samaritan Regional Health Center
🇺🇸
Mount Vernon, Illinois, United States
Radiation Oncology of Northern Illinois
🇺🇸
Ottawa, Illinois, United States
Illinois CancerCare-Pekin
🇺🇸
Pekin, Illinois, United States
SwedishAmerican Regional Cancer Center/ACT
🇺🇸
Rockford, Illinois, United States
Illinois Cancer Specialists-Niles
🇺🇸
Niles, Illinois, United States
Illinois CancerCare-Peru
🇺🇸
Peru, Illinois, United States
Valley Radiation Oncology
🇺🇸
Peru, Illinois, United States
Illinois CancerCare-Ottawa Clinic
🇺🇸
Ottawa, Illinois, United States
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
🇺🇸
Peoria, Illinois, United States
Methodist Medical Center of Illinois
🇺🇸
Peoria, Illinois, United States
Central Illinois Hematology Oncology Center
🇺🇸
Springfield, Illinois, United States
North Shore Medical Center
🇺🇸
Skokie, Illinois, United States
Springfield Clinic
🇺🇸
Springfield, Illinois, United States
IU Health Central Indiana Cancer Centers-East
🇺🇸
Indianapolis, Indiana, United States
McFarland Clinic PC-William R Bliss Cancer Center
🇺🇸
Ames, Iowa, United States
McFarland Clinic PC-Boone
🇺🇸
Boone, Iowa, United States
Alegent Health Mercy Hospital
🇺🇸
Council Bluffs, Iowa, United States
McFarland Clinic PC-Jefferson
🇺🇸
Jefferson, Iowa, United States
University of Iowa/Holden Comprehensive Cancer Center
🇺🇸
Iowa City, Iowa, United States
McFarland Clinic PC-Marshalltown
🇺🇸
Marshalltown, Iowa, United States
Siouxland Regional Cancer Center
🇺🇸
Sioux City, Iowa, United States
Kinston Medical Specialists PA
🇺🇸
Kinston, North Carolina, United States
Angel Medical Center
🇺🇸
Franklin, North Carolina, United States
Blue Ridge Regional Hospital
🇺🇸
Spruce Pine, North Carolina, United States
Summa Akron City Hospital/Cooper Cancer Center
🇺🇸
Akron, Ohio, United States
Anchorage Oncology Centre
🇺🇸
Anchorage, Alaska, United States
Oncology Hematology Care Inc-Eden Park
🇺🇸
Cincinnati, Ohio, United States
Oncology Hematology Care Inc-Mercy West
🇺🇸
Cincinnati, Ohio, United States
Miami Valley Hospital South
🇺🇸
Centerville, Ohio, United States
Katmai Oncology Group
🇺🇸
Anchorage, Alaska, United States
Case Western Reserve University
🇺🇸
Cleveland, Ohio, United States
TriHealth Cancer Institute-Westside
🇺🇸
Cincinnati, Ohio, United States
Miami Valley Hospital
🇺🇸
Dayton, Ohio, United States
Samaritan North Health Center
🇺🇸
Dayton, Ohio, United States
Wright-Patterson Medical Center
🇺🇸
Wright-Patterson Air Force Base, Ohio, United States
Springfield Regional Medical Center
🇺🇸
Springfield, Ohio, United States
Upper Valley Medical Center
🇺🇸
Troy, Ohio, United States
Greene Memorial Hospital
🇺🇸
Xenia, Ohio, United States
PeaceHealth Saint Joseph Medical Center
🇺🇸
Bellingham, Washington, United States
WellSpan Health-York Hospital
🇺🇸
York, Pennsylvania, United States
Saint Elizabeth Hospital
🇺🇸
Enumclaw, Washington, United States
University of Arizona Cancer Center-North Campus
🇺🇸
Tucson, Arizona, United States
City of Hope Comprehensive Cancer Center
🇺🇸
Duarte, California, United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center
🇺🇸
Burbank, California, United States
Mercy Cancer Center-Hot Springs
🇺🇸
Hot Springs, Arkansas, United States
UC San Diego Moores Cancer Center
🇺🇸
La Jolla, California, United States
Northside Hospital-Forsyth
🇺🇸
Cumming, Georgia, United States
Kootenai Medical Center
🇺🇸
Coeur d'Alene, Idaho, United States
Saint Luke's Mountain States Tumor Institute - Fruitland
🇺🇸
Fruitland, Idaho, United States
Saint Luke's Mountain States Tumor Institute - Nampa
🇺🇸
Nampa, Idaho, United States
Kootenai Cancer Center
🇺🇸
Post Falls, Idaho, United States
Kootenai Cancer Clinic
🇺🇸
Sandpoint, Idaho, United States
Mount Sinai Hospital Medical Center
🇺🇸
Chicago, Illinois, United States
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
🇺🇸
Pekin, Illinois, United States
OSF Saint Francis Medical Center
🇺🇸
Peoria, Illinois, United States
Illinois CancerCare-Princeton
🇺🇸
Princeton, Illinois, United States
Memorial Medical Center
🇺🇸
Springfield, Illinois, United States
Fort Wayne Medical Oncology and Hematology Inc-Parkview
🇺🇸
Fort Wayne, Indiana, United States
Medical Oncology and Hematology Associates-West Des Moines
🇺🇸
Clive, Iowa, United States
Mercy Medical Center-West Lakes
🇺🇸
West Des Moines, Iowa, United States
Saint Luke's Regional Medical Center
🇺🇸
Sioux City, Iowa, United States
Mercy Medical Center-Sioux City
🇺🇸
Sioux City, Iowa, United States
Cancer Center of Kansas - McPherson
🇺🇸
McPherson, Kansas, United States
Cancer Center of Kansas-Wichita Medical Arts Tower
🇺🇸
Wichita, Kansas, United States
Wesley Medical Center
🇺🇸
Wichita, Kansas, United States
Cancer Center of Kansas - Winfield
🇺🇸
Winfield, Kansas, United States
Commonwealth Cancer Center-Corbin
🇺🇸
Corbin, Kentucky, United States
Jewish Hospital Medical Center South
🇺🇸
Shepherdsville, Kentucky, United States
Baton Rouge General Medical Center
🇺🇸
Baton Rouge, Louisiana, United States
West Jefferson Medical Center
🇺🇸
Marrero, Louisiana, United States
Harold Alfond Center for Cancer Care
🇺🇸
Augusta, Maine, United States
Eastern Maine Medical Center
🇺🇸
Bangor, Maine, United States
Lafayette Family Cancer Center-EMMC
🇺🇸
Brewer, Maine, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
🇺🇸
Baltimore, Maryland, United States
Beaumont Hospital-Dearborn
🇺🇸
Dearborn, Michigan, United States
Saint Peter's Community Hospital
🇺🇸
Helena, Montana, United States
Spectrum Health at Butterworth Campus
🇺🇸
Grand Rapids, Michigan, United States
Bronson Methodist Hospital
🇺🇸
Kalamazoo, Michigan, United States
Lake Huron Medical Center
🇺🇸
Port Huron, Michigan, United States
Assarian Cancer Center
🇺🇸
Novi, Michigan, United States
Hutchinson Area Health Care
🇺🇸
Hutchinson, Minnesota, United States
Saint John's Hospital - Healtheast
🇺🇸
Maplewood, Minnesota, United States
North Memorial Medical Health Center
🇺🇸
Robbinsdale, Minnesota, United States
Metro Minnesota Community Oncology Research Consortium
🇺🇸
Saint Louis Park, Minnesota, United States
Park Nicollet Clinic - Saint Louis Park
🇺🇸
Saint Louis Park, Minnesota, United States
Saint Francis Regional Medical Center
🇺🇸
Shakopee, Minnesota, United States
United Hospital
🇺🇸
Saint Paul, Minnesota, United States
Ridgeview Medical Center
🇺🇸
Waconia, Minnesota, United States
Parkland Health Center-Bonne Terre
🇺🇸
Bonne Terre, Missouri, United States
CoxHealth Cancer Center
🇺🇸
Branson, Missouri, United States
Centerpoint Medical Center LLC
🇺🇸
Independence, Missouri, United States
Delbert Day Cancer Institute at PCRMC
🇺🇸
Rolla, Missouri, United States
Saint John's Clinic-Rolla-Cancer and Hematology
🇺🇸
Rolla, Missouri, United States
Heartland Regional Medical Center
🇺🇸
Saint Joseph, Missouri, United States
Washington University School of Medicine
🇺🇸
Saint Louis, Missouri, United States
Missouri Baptist Medical Center
🇺🇸
Saint Louis, Missouri, United States
Mercy Hospital Saint Louis
🇺🇸
Saint Louis, Missouri, United States
Sainte Genevieve County Memorial Hospital
🇺🇸
Sainte Genevieve, Missouri, United States
Mercy Hospital Springfield
🇺🇸
Springfield, Missouri, United States
CoxHealth South Hospital
🇺🇸
Springfield, Missouri, United States
Missouri Baptist Sullivan Hospital
🇺🇸
Sullivan, Missouri, United States
Missouri Baptist Outpatient Center-Sunset Hills
🇺🇸
Sunset Hills, Missouri, United States
Billings Clinic Cancer Center
🇺🇸
Billings, Montana, United States
Saint Vincent Healthcare
🇺🇸
Billings, Montana, United States
Montana Cancer Consortium NCORP
🇺🇸
Billings, Montana, United States
Benefis Healthcare- Sletten Cancer Institute
🇺🇸
Great Falls, Montana, United States
Great Falls Clinic
🇺🇸
Great Falls, Montana, United States
Kalispell Regional Medical Center
🇺🇸
Kalispell, Montana, United States
Montana Cancer Specialists
🇺🇸
Missoula, Montana, United States
Community Medical Hospital
🇺🇸
Missoula, Montana, United States
Saint Patrick Hospital - Community Hospital
🇺🇸
Missoula, Montana, United States
CHI Health Saint Francis
🇺🇸
Grand Island, Nebraska, United States
Heartland Hematology and Oncology
🇺🇸
Kearney, Nebraska, United States
Saint Elizabeth Regional Medical Center
🇺🇸
Lincoln, Nebraska, United States
Dartmouth Hitchcock Medical Center
🇺🇸
Lebanon, New Hampshire, United States
Saint Joseph's Regional Medical Center
🇺🇸
Paterson, New Jersey, United States
Roswell Park Cancer Institute
🇺🇸
Buffalo, New York, United States
North Shore University Hospital
🇺🇸
Manhasset, New York, United States
Northwell Health/Center for Advanced Medicine
🇺🇸
New Hyde Park, New York, United States
Long Island Jewish Medical Center
🇺🇸
New Hyde Park, New York, United States
University of California Davis Comprehensive Cancer Center
🇺🇸
Sacramento, California, United States
Moffitt Cancer Center
🇺🇸
Tampa, Florida, United States
Mayo Clinic
🇺🇸
Rochester, Minnesota, United States
Alegent Health Immanuel Medical Center
🇺🇸
Omaha, Nebraska, United States
Michigan Cancer Research Consortium NCORP
🇺🇸
Ann Arbor, Michigan, United States
Mount Sinai Hospital
🇺🇸
New York, New York, United States
Alegent Health Bergan Mercy Medical Center
🇺🇸
Omaha, Nebraska, United States
Alegent Health Lakeside Hospital
🇺🇸
Omaha, Nebraska, United States
Hemotology and Oncology Consultants PC
🇺🇸
Omaha, Nebraska, United States
University of Nebraska Medical Center
🇺🇸
Omaha, Nebraska, United States
Creighton University Medical Center
🇺🇸
Omaha, Nebraska, United States
University of Rochester
🇺🇸
Rochester, New York, United States
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
🇺🇸
Winston-Salem, North Carolina, United States
Cancer Care of Western North Carolina
🇺🇸
Asheville, North Carolina, United States
Froedtert and the Medical College of Wisconsin
🇺🇸
Milwaukee, Wisconsin, United States
Mission Hospital-Memorial Campus
🇺🇸
Asheville, North Carolina, United States
Mountain Radiation Oncology
🇺🇸
Asheville, North Carolina, United States
Asheville Hematology-Oncology Associates
🇺🇸
Asheville, North Carolina, United States
Hope Women's Cancer Centers-Asheville
🇺🇸
Asheville, North Carolina, United States
Kettering Medical Center
🇺🇸
Kettering, Ohio, United States
Springfield Regional Cancer Center
🇺🇸
Springfield, Ohio, United States
Warren Clinic Oncology-Tulsa
🇺🇸
Tulsa, Oklahoma, United States
Clackamas Radiation Oncology Center
🇺🇸
Clackamas, Oregon, United States
Providence Saint Vincent Medical Center
🇺🇸
Portland, Oregon, United States
University of Pennsylvania/Abramson Cancer Center
🇺🇸
Philadelphia, Pennsylvania, United States
Vanderbilt-Ingram Cancer Center Cool Springs
🇺🇸
Franklin, Tennessee, United States
Spartanburg Medical Center
🇺🇸
Spartanburg, South Carolina, United States
Carolina Blood and Cancer Care Associates PA-Lancaster
🇺🇸
Lancaster, South Carolina, United States
Memorial GYN Plus
🇺🇸
Ooltewah, Tennessee, United States
Ben Taub General Hospital
🇺🇸
Houston, Texas, United States
Michael E DeBakey VA Medical Center
🇺🇸
Houston, Texas, United States
Central Vermont Medical Center/National Life Cancer Treatment
🇺🇸
Berlin, Vermont, United States
Cancer Care Center at Island Hospital
🇺🇸
Anacortes, Washington, United States
Harrison Medical Center
🇺🇸
Bremerton, Washington, United States
Providence Regional Cancer Partnership
🇺🇸
Everett, Washington, United States
Saint Clare Hospital
🇺🇸
Lakewood, Washington, United States
Minor and James Medical PLLC
🇺🇸
Seattle, Washington, United States
PeaceHealth Saint John Medical Center
🇺🇸
Longview, Washington, United States
Providence Regional Cancer System-Lacey
🇺🇸
Lacey, Washington, United States
University of Washington Medical Center
🇺🇸
Seattle, Washington, United States
Swedish Medical Center-First Hill
🇺🇸
Seattle, Washington, United States
United General Hospital
🇺🇸
Sedro-Woolley, Washington, United States
Providence Regional Cancer System-Shelton
🇺🇸
Shelton, Washington, United States
Rockwood Clinic Cancer Treatment Center-Valley
🇺🇸
Spokane Valley, Washington, United States
Cancer Care Northwest - Spokane South
🇺🇸
Spokane, Washington, United States
Rockwood Cancer Treatment Center-DHEC-Downtown
🇺🇸
Spokane, Washington, United States
Evergreen Hematology and Oncology PS
🇺🇸
Spokane, Washington, United States
Rockwood Clinic
🇺🇸
Spokane, Washington, United States
Wenatchee Valley Hospital and Clinics
🇺🇸
Wenatchee, Washington, United States
Providence Saint Mary Regional Cancer Center
🇺🇸
Walla Walla, Washington, United States
PeaceHealth Southwest Medical Center
🇺🇸
Vancouver, Washington, United States
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
🇺🇸
Yakima, Washington, United States
Providence Regional Cancer System-Yelm
🇺🇸
Yelm, Washington, United States
Marshfield Clinic Cancer Center at Sacred Heart
🇺🇸
Eau Claire, Wisconsin, United States
Sacred Heart Hospital
🇺🇸
Eau Claire, Wisconsin, United States
Green Bay Oncology at Saint Vincent Hospital
🇺🇸
Green Bay, Wisconsin, United States
Saint Vincent Hospital Cancer Center Green Bay
🇺🇸
Green Bay, Wisconsin, United States
Green Bay Oncology Limited at Saint Mary's Hospital
🇺🇸
Green Bay, Wisconsin, United States
Saint Vincent Hospital Cancer Center at Saint Mary's
🇺🇸
Green Bay, Wisconsin, United States
UW Cancer Center Johnson Creek
🇺🇸
Johnson Creek, Wisconsin, United States
Gundersen Lutheran Medical Center
🇺🇸
La Crosse, Wisconsin, United States
Marshfield Medical Center
🇺🇸
Marshfield, Wisconsin, United States
Bay Area Medical Center
🇺🇸
Marinette, Wisconsin, United States
Holy Family Memorial Hospital
🇺🇸
Manitowoc, Wisconsin, United States
Marshfield Clinic
🇺🇸
Marshfield, Wisconsin, United States
ProHealth D N Greenwald Center
🇺🇸
Mukwonago, Wisconsin, United States
Green Bay Oncology - Oconto Falls
🇺🇸
Oconto Falls, Wisconsin, United States
ProHealth Oconomowoc Memorial Hospital
🇺🇸
Oconomowoc, Wisconsin, United States
Marshfield Clinic at James Beck Cancer Center
🇺🇸
Rhinelander, Wisconsin, United States
Marshfield Clinic-Rice Lake Center
🇺🇸
Rice Lake, Wisconsin, United States
HSHS Saint Nicholas Hospital
🇺🇸
Sheboygan, Wisconsin, United States
Green Bay Oncology - Sturgeon Bay
🇺🇸
Sturgeon Bay, Wisconsin, United States
UW Cancer Center at ProHealth Care
🇺🇸
Waukesha, Wisconsin, United States
Saint Clare's Hospital
🇺🇸
Weston, Wisconsin, United States
Marshfield Clinic-Wausau Center
🇺🇸
Wausau, Wisconsin, United States
Marshfield Clinic - Weston Center
🇺🇸
Weston, Wisconsin, United States
Rocky Mountain Oncology
🇺🇸
Casper, Wyoming, United States
Big Horn Basin Cancer Center
🇺🇸
Cody, Wyoming, United States
Tom Baker Cancer Centre
🇨🇦
Calgary, Alberta, Canada
Atlantic Health Sciences Corporation-Saint John Regional Hospital
🇨🇦
Saint John, New Brunswick, Canada
QEII Health Sciences Centre/Nova Scotia Health Authority
🇨🇦
Halifax, Nova Scotia, Canada
Swedish Medical Center-Ballard Campus
🇺🇸
Seattle, Washington, United States
Kaiser Permanente Washington
🇺🇸
Seattle, Washington, United States
Oncology Hematology Care Inc-Crestview
🇺🇸
Crestview Hills, Kentucky, United States
University of New Mexico Cancer Center
🇺🇸
Albuquerque, New Mexico, United States
Illinois CancerCare-Eureka
🇺🇸
Eureka, Illinois, United States
Southern Illinois University School of Medicine
🇺🇸
Springfield, Illinois, United States
Mercy Cancer Center-West Lakes
🇺🇸
Clive, Iowa, United States
Reid Health
🇺🇸
Richmond, Indiana, United States
Illinois CancerCare-Galesburg
🇺🇸
Galesburg, Illinois, United States
Presence Saint Mary's Hospital
🇺🇸
Kankakee, Illinois, United States
Hematology Oncology Associates of Illinois - Skokie
🇺🇸
Skokie, Illinois, United States
Cancer Care Specialists of Illinois-Swansea
🇺🇸
Swansea, Illinois, United States
Compass Oncology Vancouver
🇺🇸
Vancouver, Washington, United States
Borgess Medical Center
🇺🇸
Kalamazoo, Michigan, United States
Yale University
🇺🇸
New Haven, Connecticut, United States
Jewish Hospital
🇺🇸
Louisville, Kentucky, United States
Jewish Hospital Medical Center Northeast
🇺🇸
Louisville, Kentucky, United States
Saints Mary and Elizabeth Hospital
🇺🇸
Louisville, Kentucky, United States
Saint Luke's Hospital of Kansas City
🇺🇸
Kansas City, Missouri, United States
Heartland Hematology and Oncology Associates Incorporated
🇺🇸
Kansas City, Missouri, United States
Research Medical Center
🇺🇸
Kansas City, Missouri, United States
Medical University of South Carolina
🇺🇸
Charleston, South Carolina, United States
Tulane University Health Sciences Center
🇺🇸
New Orleans, Louisiana, United States
Virginia Commonwealth University/Massey Cancer Center
🇺🇸
Richmond, Virginia, United States
Providence Alaska Medical Center
🇺🇸
Anchorage, Alaska, United States
Providence Oncology and Hematology Care Southeast
🇺🇸
Clackamas, Oregon, United States
Saint Luke's Mountain States Tumor Institute
🇺🇸
Boise, Idaho, United States
West Michigan Cancer Center
🇺🇸
Kalamazoo, Michigan, United States
Sparrow Hospital
🇺🇸
Lansing, Michigan, United States
Providence Portland Medical Center
🇺🇸
Portland, Oregon, United States
University of Michigan Comprehensive Cancer Center
🇺🇸
Ann Arbor, Michigan, United States
Logan Regional Hospital
🇺🇸
Logan, Utah, United States
Saint John Hospital and Medical Center
🇺🇸
Detroit, Michigan, United States
Saint Joseph Mercy Hospital
🇺🇸
Ann Arbor, Michigan, United States
Weisberg Cancer Treatment Center
🇺🇸
Farmington Hills, Michigan, United States
Hurley Medical Center
🇺🇸
Flint, Michigan, United States
Cancer Research Consortium of West Michigan NCORP
🇺🇸
Grand Rapids, Michigan, United States
Mercy Health Saint Mary's
🇺🇸
Grand Rapids, Michigan, United States
Saint Luke's Mountain States Tumor Institute - Meridian
🇺🇸
Meridian, Idaho, United States
Bronson Battle Creek
🇺🇸
Battle Creek, Michigan, United States
Allegiance Health
🇺🇸
Jackson, Michigan, United States
Saint Mary Mercy Hospital
🇺🇸
Livonia, Michigan, United States
Mercy Health Mercy Campus
🇺🇸
Muskegon, Michigan, United States
Spectrum Health Big Rapids Hospital
🇺🇸
Big Rapids, Michigan, United States
Green Bay Oncology - Escanaba
🇺🇸
Escanaba, Michigan, United States
Green Bay Oncology - Iron Mountain
🇺🇸
Iron Mountain, Michigan, United States
Providence Hospital-Southfield Cancer Center
🇺🇸
Southfield, Michigan, United States
Munson Medical Center
🇺🇸
Traverse City, Michigan, United States
University of Mississippi Medical Center
🇺🇸
Jackson, Mississippi, United States
University of Vermont College of Medicine
🇺🇸
Burlington, Vermont, United States
Saint John Macomb-Oakland Hospital
🇺🇸
Warren, Michigan, United States
Memorial Hospital
🇺🇸
Chattanooga, Tennessee, United States
Saint Joseph Mercy Oakland
🇺🇸
Pontiac, Michigan, United States
Saint Mary's of Michigan
🇺🇸
Saginaw, Michigan, United States
Intermountain Medical Center
🇺🇸
Murray, Utah, United States
Marshfield Clinic - Wisconsin Rapids Center
🇺🇸
Wisconsin Rapids, Wisconsin, United States
Saint Charles Health System
🇺🇸
Bend, Oregon, United States
Providence Willamette Falls Medical Center
🇺🇸
Oregon City, Oregon, United States
Vanderbilt University/Ingram Cancer Center
🇺🇸
Nashville, Tennessee, United States
Gibbs Cancer Center-Pelham
🇺🇸
Greer, South Carolina, United States
Wake Forest University Health Sciences
🇺🇸
Winston-Salem, North Carolina, United States
Spectrum Health Reed City Hospital
🇺🇸
Reed City, Michigan, United States
Providence Milwaukie Hospital
🇺🇸
Milwaukie, Oregon, United States
MGC Hematology Oncology-Union
🇺🇸
Union, South Carolina, United States
Sandra L Maxwell Cancer Center
🇺🇸
Cedar City, Utah, United States
Utah Valley Regional Medical Center
🇺🇸
Provo, Utah, United States
Pulmonary Medicine Center of Chattanooga-Hixson
🇺🇸
Hixson, Tennessee, United States
AnMed Health Cancer Center
🇺🇸
Anderson, South Carolina, United States
LDS Hospital
🇺🇸
Salt Lake City, Utah, United States
Carolina Blood and Cancer Care Associates PA
🇺🇸
Rock Hill, South Carolina, United States
Marshfield Clinic-Minocqua Center
🇺🇸
Minocqua, Wisconsin, United States
Marshfield Clinic Cancer Care at Saint Michael's Hospital
🇺🇸
Stevens Point, Wisconsin, United States
The Moncton Hospital
🇨🇦
Moncton, New Brunswick, Canada
Dixie Medical Center Regional Cancer Center
🇺🇸
Saint George, Utah, United States
CIUSSSEMTL-Hopital Maisonneuve-Rosemont
🇨🇦
Montreal, Quebec, Canada
ProHealth Waukesha Memorial Hospital
🇺🇸
Waukesha, Wisconsin, United States
University of Florida Health Science Center - Gainesville
🇺🇸
Gainesville, Florida, United States
Medical Oncology and Hematology Associates-Laurel
🇺🇸
Des Moines, Iowa, United States
Saint Joseph Radiation Oncology Resource Center
🇺🇸
Lexington, Kentucky, United States
University of Kentucky/Markey Cancer Center
🇺🇸
Lexington, Kentucky, United States
University of Wisconsin Hospital and Clinics
🇺🇸
Madison, Wisconsin, United States
Kansas City NCI Community Oncology Research Program
🇺🇸
Prairie Village, Kansas, United States
Cancer Center of Western Wisconsin
🇺🇸
New Richmond, Wisconsin, United States
Cancer Center of Kansas-Manhattan
🇺🇸
Manhattan, Kansas, United States
Cancer Center of Kansas - Fort Scott
🇺🇸
Fort Scott, Kansas, United States
Highline Medical Center-Main Campus
🇺🇸
Burien, Washington, United States
Summa Barberton Hospital
🇺🇸
Barberton, Ohio, United States